Beiersdorf stock weighs Derma strength against NIVEA pressure
Published on 11/11/2026 at 10:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMixed third-quarter performance
- Derma organic sales rose 10.6% and La Prairie grew 8.5% in the third quarter.
- NIVEA organic sales fell 4.9%, although global sell-out continued to grow.
- Beiersdorf maintained its full-year outlook for organic sales and EBIT margin.
Beiersdorf reported a mixed third-quarter performance on October 27, with strong growth in its Derma and La Prairie businesses offset by continued weakness at NIVEA. The company confirmed its full-year 2026 guidance in the official results release.
Beiersdorf stock traded at 84.75 euros on Lang & Schwarz at 10:16 CET on Wednesday, November 11, 0.69 percent below the Xetra close of Tuesday, November 10. The comparison reflects the latest available Xetra session before the current trading day.
Derma remains the growth engine
The Derma business, which includes Eucerin and Aquaphor, delivered organic sales growth of 10.6% in the quarter. Beiersdorf said growth was broad-based across regions and categories, supported by innovation and expansion into new market segments. The company also highlighted the expansion of Aquaphor into body care in North America.
La Prairie accelerated its performance with organic sales growth of 8.5%, supported by continued momentum in China. Health Care, including Hansaplast and Elastoplast, added organic growth of 5.7%. At group level, third-quarter sales reached 2.362 billion euros, down 1.3% organically but up 0.4% on a reported basis.
NIVEA turnaround remains central
NIVEA organic sales declined 4.9% in the third quarter. Beiersdorf attributed the pressure to temporary sell-in effects, trade-related tensions and inventory destocking. The company said sales dynamics improved compared with the second quarter and that these effects should gradually fade by year-end.
Global NIVEA sell-out continued to grow, which management described as an early sign that its rebalancing measures are gaining traction. The turnaround plan focuses on broader innovation, a stronger value-for-money proposition and greater use of local consumer insights. The FACE+ launch in Europe is one of the initiatives already under way.
Beiersdorf is also increasing consumer-facing investment, including a five-year NIVEA SUN partnership with the Tour de France beginning in 2027. For investors, the key question is whether improving sell-out can translate into healthier inventories and stronger shipments without putting excessive pressure on margins.
Guidance stays cautious
For the first nine months, group sales stood at 7.314 billion euros, representing an organic decline of 2.8%. The Consumer business posted an organic decline of 2.9% over the same period, while tesa sales fell 4.3% organically in the quarter as semiconductor shortages weighed on its Electronics business.
Beiersdorf continues to expect a low-single-digit organic sales decline for the full year. The company targets an EBIT margin excluding special factors of at least 11.0% in Consumer and at least 11.8% at group level. The outlook leaves execution of the NIVEA turnaround and the development of tesa's Electronics business as the main operating issues for the remainder of 2026.
Beiersdorf stock at a glance
- Company: Beiersdorf AG
- ISIN: DE0005200000
- Xetra ticker: BEI.DE
- Trading venue: Lang & Schwarz
- Price: 84.75 euros at 10:16 CET on November 11, 2026
- Change: 0.69% below the Xetra close of November 10, 2026
- Xetra close: 85.34 euros on November 10, 2026
European investors are tracking Beiersdorf alongside the DAX market environment as consumer-sector earnings remain sensitive to inventory trends and brand momentum.
